Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started ...

This Research Topic is the second volume of the “Immune Responses Against Tumors - From the Bench to the Bedside” Community Series. Please see Volume I ...

Approximately 90% of all kidney cancers involve renal cell carcinoma, against which researchers are racing to find more effective therapies. One of the major challenges in treating this and other ...

Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system's ability to ...

A protein identified by researchers at UT Southwestern Medical Center may drive resistance to immune checkpoint inhibitors, a ...

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.

Antigen-presenting cells (APCs), such as dendritic cells and macrophages, are essential for initiating and regulation of anti-tumor T cell responses.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system more effectively than traditional therapies, particularly against evasive and ...